Background: The goal of the National Smallpox Vaccination Program was to vaccinate a cadre of healthcare workers and first responders who could care for smallpox patients in the event of an attack.
Methods: Using a convenience sample of 36 health departments and 34 hospitals in California, we conducted a telephone interview between July 2003 and April 2004 of healthcare workers and first responders to determine predictors of smallpox vaccination.
Findings: The response rate was 54.1%. Of 477 respondents with no contraindications to vaccination, 106 were vaccinated and 371 were unvaccinated. Among the vaccinated, the leading reason for vaccination was wanting to be part of a smallpox response team (74%). Among the unvaccinated, leading reasons for not being vaccinated included thinking the risk of smallpox was not high enough (25%) and concern about side effects (19%). Factors independently associated with vaccination include previous smallpox vaccination (adjusted odds ratio [AOR]=4.1, 95% confidence interval [CI]=1.2-14.1), having little or no concern about vaccine adverse events (AOR=3.0, CI=1.3-7.0, compared with somewhat/very), reporting their employer had a policy to reimburse for travel or other out of pocket costs (AOR=2.5, CI=1.1-5.7, compared with no policy), very high to high chance of compensation if adverse events occurred (AOR=2.9, CI=1.2-6.3, compared with low chance), and answering in the negative to questions about concerns about potential costs. Blacks were less likely than whites to be vaccinated (AOR=0.04, CI=0.03-0.6).
Conclusions: Clearly communicating the risks and benefits of vaccination and addressing issues of cost, convenience, and compensation may be important for any program where vaccination is provided in the national interest and when the direct benefits of vaccination are unknown.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amepre.2007.02.002 | DOI Listing |
Can Commun Dis Rep
January 2025
Department of Medicine, University of Alberta, Edmonton, AB.
Background: Mpox is a viral illness related to smallpox. It can cause flu-like symptoms and a rash, and in severe cases, can lead to hospitalization or death. The Imvamune® vaccine offers protection against mpox.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
January 2025
School of Human Sciences, London Metropolitan University, London, UK.
Mpox, formerly known as monkeypox, is a zoonotic disease caused by the Mpox virus (MPXV), which has recently attracted global attention due to its potential for widespread outbreaks. Initially identified in 1958, MPXV primarily spreads to humans through contact with infected wild animals, particularly rodents. Historically confined to Africa, the virus has expanded beyond endemic regions, with notable outbreaks in Europe and North America in 2022, especially among men who have sex with men (MSM).
View Article and Find Full Text PDFMicroorganisms
December 2024
Targeted Therapy Team, Institute for Cancer Research, 237 Fulham Road, London SW3 6JB, UK.
The COVID-19 and mpox crisis has reminded the world of the potentially catastrophic consequences of biological agents. Aside from the natural risk, biological agents can also be weaponized or used for bioterrorism. Dissemination in a population or among livestock could be used to destabilize a nation by creating a climate of terror, by negatively impacting the economy and undermining institutions.
View Article and Find Full Text PDFJ Trop Med
December 2024
Department of Infectious Disease, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran.
After the global impact of the COVID-19 pandemic, concerns over virus transmission have risen. A state of health emergency was declared in 2022 due to Clade 2 of the monkeypox (MPOX) virus. In August 2024, another emergency was declared by the World Health Organization (WHO) because of the widespread Clade 1b, which caused a more severe and lethal disease.
View Article and Find Full Text PDFVaccine
January 2025
Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Electronic address:
In recent years, human mpox has made multiple resurges, prompting public health professionals to consider factors that lead to the increased risk for the reemergence of other orthopoxviruses. Due to the genetic similarity between orthopoxviruses, vaccinia vaccines used to prevent smallpox transmission are also indicated and have been used for mpox infection prevention and control. In this study, cross-reactive immunity for mpox was observed among individuals with self-reported history of smallpox vaccination.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!